44 Wealth Management LLC bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,809 shares of the medical instruments supplier's stock, valued at approximately $414,000.
Several other institutional investors also recently bought and sold shares of BDX. Brighton Jones LLC boosted its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after acquiring an additional 877 shares in the last quarter. Hara Capital LLC increased its stake in shares of Becton, Dickinson and Company by 26.4% in the 4th quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier's stock valued at $76,000 after purchasing an additional 70 shares in the last quarter. Mission Wealth Management LP acquired a new position in Becton, Dickinson and Company in the 4th quarter worth about $262,000. Assetmark Inc. boosted its position in Becton, Dickinson and Company by 51.0% during the fourth quarter. Assetmark Inc. now owns 51,180 shares of the medical instruments supplier's stock worth $11,611,000 after purchasing an additional 17,292 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $21,607,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, EVP Michael David Garrison sold 479 shares of the firm's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $964,107.36. This trade represents a 8.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 1,166 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. The trade was a 20.31% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.36% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently issued reports on BDX. Piper Sandler lowered Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Morgan Stanley decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Wells Fargo & Company cut shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target on the stock. in a research note on Friday, May 2nd. Finally, Stifel Nicolaus lowered their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $219.22.
Check Out Our Latest Report on Becton, Dickinson and Company
Becton, Dickinson and Company Stock Performance
NYSE BDX opened at $176.16 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. The stock's fifty day moving average is $173.94 and its two-hundred day moving average is $207.80. The firm has a market capitalization of $50.49 billion, a P/E ratio of 33.62, a price-to-earnings-growth ratio of 1.33 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter in the previous year, the firm earned $3.17 EPS. The company's quarterly revenue was up 4.5% compared to the same quarter last year. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.36%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's payout ratio is presently 79.39%.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
